Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation

Circulation Journal

Volumn 70, Issue 9, 2006, Pages 1138-1141

  Fujiki, Akira ^a   Sakamoto, Tamotsu ^a   Iwamoto, Jotaro ^a   Nishida, Kunihiro ^a   Nagasawa, Hidehiko ^a   Mizumaki, Koichi ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Antiarrhythmic drug; Aprindine; Atrial fibrillation; Bepridil; Defibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; SINUS RHYTHM;

ANTI-ARRHYTHMIA AGENTS; APRINDINE; ATRIAL FIBRILLATION; BEPRIDIL; DRUG COMBINATIONS; DRUG RESISTANCE; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED;

EID: 33748652509     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1138     Document Type: Article

References (11)

1. Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81: 1450-1454.
2. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475.
3. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
4. Komatsu T, Nakamura S, Suzuki O, Horiuchi D, Yomogida K, Okumura K. Long-term prognosis of patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004; 68: 729-733.
5. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-496.
6. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR, et al. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983; 52: 188-199.
7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
8. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997; 96: 4027-4035.
9. Wyse DG, Gersh BJ. Atrial fibrillation: A perspective: Thinking inside and outside the box. Circulation 2004; 109: 3089-3095.
10. Fujiki A, Sakabe M, Nishida K, Sugao M, Tsuneda T, Iwamoto J, et al. Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine. Circ J 2004; 68: 1139-1145.
11. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666.